These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10870127)

  • 1. Investigation of minimal residual disease in adult Ph1 positive acute lymphoblastic leukemia by a combination of cell sorting and fluorescence in situ hybridization: a preliminary study on 6 cases.
    Cambier N; Soenen-Cornu V; Laï JL; Cosson A; Fenaux P; Preudhomme C
    Haematologica; 2000 Jun; 85(6):664-5. PubMed ID: 10870127
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automated detection of residual leukemic cells by consecutive immunolabeling for CD10 and fluorescence in situ hybridization for ETV6/RUNX1 rearrangement in childhood acute lymphoblastic leukemia.
    Alpár D; Kajtár B; Kneif M; Jáksó P; László R; Kereskai L; Pajor L
    Cancer Genet Cytogenet; 2007 Feb; 173(1):23-30. PubMed ID: 17284366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late relapse of childhood acute lymphoblastic leukemia and pcr-monitoring of minimal residual disease: how much time can elapse between "molecular" and clinical relapse?
    Aricò M; Germano G; del Giudice L; Ziino O; Locatelli F; Basso G
    Haematologica; 2002 Apr; 87(4):ELT19. PubMed ID: 11940504
    [No Abstract]   [Full Text] [Related]  

  • 5. Approaches for cytogenetic and molecular analyses of small flow-sorted cell populations from childhood leukemia bone marrow samples.
    Obro NF; Madsen HO; Ryder LP; Andersen MK; Schmiegelow K; Marquart HV
    J Immunol Methods; 2011 Jun; 369(1-2):69-73. PubMed ID: 21570982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined cell sorting and FISH for detection of minimal residual disease in bone marrow of children with acute leukemia or solid tumors.
    Sainati L; Spinelli M; Leszl A; Cocito MG; Stella M; Basso G
    Eur J Histochem; 1997; 41 Suppl 2():167-8. PubMed ID: 9859833
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of simplified strategies to evaluate early treatment response in childhood acute lymphoblastic leukemia.
    Scrideli CA; de Paula Queiróz R; Bernardes JE; Defavery R; Valera ET; Tone LG
    Leuk Res; 2006 Aug; 30(8):1049-52. PubMed ID: 16406015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis.
    Foroni L; Harrison CJ; Hoffbrand AV; Potter MN
    Br J Haematol; 1999 Apr; 105(1):7-24. PubMed ID: 10366253
    [No Abstract]   [Full Text] [Related]  

  • 9. [Minimal residual disease. Methodologies and clinical implications].
    Ortega M; Coll MD; Solé F; Caballín MR
    Sangre (Barc); 1999 Aug; 44(4):283-90. PubMed ID: 10589280
    [No Abstract]   [Full Text] [Related]  

  • 10. Minimal residual disease in hematologic malignancies.
    San-Miguel JF; Bartram C; Campana D; Andreeff M
    Rev Invest Clin; 1994 Apr; Suppl():147-52. PubMed ID: 7886299
    [No Abstract]   [Full Text] [Related]  

  • 11. The detection and significance of minimal residual disease in acute and chronic leukemia.
    Chung NG; Buxhofer-Ausch V; Radich JP
    Tissue Antigens; 2006 Nov; 68(5):371-85. PubMed ID: 17092250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring minimal residual disease in pediatric hematologic malignancies.
    Campana D
    Clin Adv Hematol Oncol; 2007 Nov; 5(11):876-7, 915. PubMed ID: 18185484
    [No Abstract]   [Full Text] [Related]  

  • 13. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
    Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
    Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
    Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
    Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of a chemiluminescent methodology for detection of minimal residual disease in childhood acute lymphoblastic leukemia.
    Lo Nigro L; Poli A; Mirabile E; Costantino F; Schilirò G
    Haematologica; 2001 Dec; 86(12):1314-6. PubMed ID: 11726326
    [No Abstract]   [Full Text] [Related]  

  • 17. Follow-up of minimal residual disease in acute childhood lymphoblastic leukemia by WT1 gene expression in the peripheral blood: the Hungarian experience.
    Magyarosy E; Varga N; Timár J; Rásó E
    Pediatr Hematol Oncol; 2003; 20(1):65-74. PubMed ID: 12687755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
    Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
    Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can minor bcr/abl translocation in acute leukemia be discriminated from major bcr/abl by extra-signal FISH analysis?
    Lee DS; Kim EC; Yoon BH; Kim WH; Yoon JH; Cho HI
    Haematologica; 2001 Sep; 86(9):991-2. PubMed ID: 11532631
    [No Abstract]   [Full Text] [Related]  

  • 20. [Cytogenetic and in situ hybridization (FISH) follow-up in minimal residual disease].
    Acevedo S
    Medicina (B Aires); 2000; 60 Suppl 2():87-90. PubMed ID: 11188939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.